VALIRX PLC ValiRx Plc
('ValiRx' or the 'Company')
Shareholder Circular and Notice of General Meeting
London, UK. 27 June 2016: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that it has today published and posted to shareholders a circular in relation to a forthcoming General Meeting, due to be held at the offices of DAC Beachcroft LLP at 100 Fetter Lane, London EC4A 1BN at 11:30 a.m. on 12th July 2016.
The directors will propose at the General Meeting a shareholder resolution seeking consent for the dis-application of pre-emptive rights.
A copy of the Circular is available on the Company's website.
*** ENDS ***
For more information, please contact:
ValiRx plc | Tel: +44 (0) 20 3008 4416 www.valirx.com |
Dr Satu Vainikka, Chief Executive | Tel: +44 (0) 20 3008 4416 |
Tarquin Edwards, Head of Communications. | Tel: +44 (0) 7879 458 364 tarquin.edwards@valirx.com |
Mark Treharne, Corporate Development Manager | Tel: +44 (0) 7736 564 686 mark.treharne@valirx.com |
Cairn Financial Advisers LLP (Nominated Adviser) | Tel: +44 (0) 20 7148 7900 |
Liam Murray / Richard Nash | |
Northland Capital Partners Limited (Broker) | Tel: +44 (0) 20 7382 1100 |
Patrick Claridge / David Hignell (Corporate Finance) John Howes / Abigail Wayne (Broking) |
ValiRx plc published this content on 27 June 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 27 June 2016 06:23:03 UTC.
Original documenthttp://tools.euroland.com/tools/PressReleases/GetPressRelease/?ID=3213760&lang=en-GB&companycode=services
Public permalinkhttp://www.publicnow.com/view/24DC80D3575059C90D21E615CEFC761706D3B8A8
